Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 14/20 | 0.42 |
| ▸ | HTR6 | P50406 | 13/20 | 0.42 |
| ▸ | DRD2 | P14416 | 12/20 | 0.42 |
| ▸ | HTR2A | P28223 | 12/20 | 0.42 |
| ▸ | HTR1A | P08908 | 3/20 | 0.40 |
| ▸ | GBA1 | P04062 | 2/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4765132 | 0.89 | GBA1 (0.39) | HTR7HTR6DRD2HTR2AGBA1 | |
| SCHEMBL4767462 | 0.88 | DRD2 (0.47) | HTR7HTR6DRD2HTR2AHTR1A | |
| Oxalic Acid SCHEMBL4772211 | 0.87 | KDM4E (0.46) | HTR7HTR6DRD2HTR2AHTR1A | |
| SCHEMBL4771141 | 0.86 | GBA1 (0.43) | HTR7HTR6DRD2HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL4770876 | 0.85 | GBA1 (0.43) | HTR7HTR6DRD2HTR2AHTR1A | |
| SCHEMBL4774328 | 0.82 | GBA1 (0.43) | HTR7HTR6DRD2HTR2AHTR1A | |
| SCHEMBL4770341 | 0.81 | DRD2 (0.47) | HTR7HTR6DRD2HTR2AHTR1A | |
| SCHEMBL4773646 | 0.81 | ROCK2 (0.53) | HTR7HTR6DRD2HTR2AHTR1A | |
| Hydrochloric Acid SCHEMBL4766031 | 0.80 | DRD2 (0.46) | HTR7HTR6DRD2HTR2AHTR1A | |
| SCHEMBL4765764 | 0.80 | ALDH1A1 (0.46) | HTR7HTR6DRD2HTR2AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1020445-B1 | FUSED PYRIDINE DERIVATIVES | EISAI R&D MAN CO LTD (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-6875761-B2 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. (JP) | 2005-04-05 | — | — | US | disclosed |
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | EISAI CO., LTD. | 2004-10-14 | — | — | US | disclosed |
| US-6790844-B2 | MUSCLE RELAXANTS; ANTISEROTONINE AGENT | EISAI CO., LTD (JP) | 2004-09-14 | — | — | US | disclosed |
| US-6340759-B1 | ANTISPASMODIC AGENTS | EISAI CO., LTD. (JP) | 2002-01-22 | — | — | US | disclosed |
| EP-1020445-A1 | FUSED PYRIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 2000-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040204421-A1 | Certain 1,3-disubstituted isoquinoline derivatives | MUSK, HTR1A, RYR1 | HTR7 17/4885HTR6 127/4885DRD2 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.